A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01878708
Recruitment Status : Terminated (Slow accrual)
First Posted : June 17, 2013
Last Update Posted : March 6, 2017
Leadiant Biosciences, Inc.
Information provided by (Responsible Party):
Philippe Armand, MD, PhD, Dana-Farber Cancer Institute

No Study Results Posted on for this Study
  Recruitment Status : Terminated
  Primary Completion Date : February 2017
  Study Completion Date : February 2017